Carregant...

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T-cells. To evade immune eradication, cancers exploit checkpoints that dampen T-cell reactivity. Immune checkpoint inhibitors (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Cell
Autors principals: Jardim, Denis L., Goodman, Aaron, Gagliato, Debora de Melo, Kurzrock, Razelle
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878292/
https://ncbi.nlm.nih.gov/pubmed/33125859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2020.10.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!